Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Hozzl · 2025-03-18T18:49:09Z

Explore the details of House Bill 1632 Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/18/2025, 6:49 PM

Summary of Bill HR 1632

Bill 119 HR 1632, also known as the Reciprocal Access to Drugs Act, aims to amend the Federal Food, Drug, and Cosmetic Act to allow for reciprocal marketing approval of certain drugs, biological products, and devices that are already authorized to be lawfully marketed in other countries. This means that if a drug or medical device has already been approved for sale in a foreign country, it can potentially be fast-tracked for approval in the United States.

The main goal of this bill is to streamline the approval process for certain medications and medical devices, potentially increasing access to new treatments for American patients. By allowing for reciprocal approval, the bill seeks to reduce the time and resources needed for new drugs and devices to enter the US market, while still maintaining safety and efficacy standards.

Supporters of the bill argue that it will help to speed up the availability of innovative treatments for patients, particularly for rare diseases or conditions where there may be limited options currently available in the US. They also believe that it will encourage international collaboration and innovation in the pharmaceutical and medical device industries. Critics of the bill, however, raise concerns about potential safety risks associated with fast-tracking approvals based on foreign regulatory standards. They argue that the US Food and Drug Administration (FDA) has rigorous testing and approval processes in place for a reason, and that these standards should not be compromised in the interest of expediency. Overall, Bill 119 HR 1632 represents an effort to modernize and improve the regulatory process for drugs and medical devices in the US, with the ultimate goal of increasing access to new treatments for American patients. The bill is currently under consideration in Congress and may undergo further revisions before potentially becoming law.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1632

Bill HR 1632 is currently in the status of Bill Introduced since February 26, 2025. Bill HR 1632 was introduced during Congress 119 and was introduced to the House on February 26, 2025. Bill HR 1632's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of February 26, 2025

Bipartisan Support of Bill HR 1632

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1632

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1632

To amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes.To amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes.

Start holding our government accountable!

Comments

Sponsors and Cosponsors of HR 1632

Chip Roy

Texas(Republican)

Andy Harris

Maryland(Republican)

Latest Bills